2. Academic Validation
  3. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma

  • Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02790-x.
Lingxi Jiang # 1 2 3,  Jiejie Qin # 1 2 3,  Yuting Dai # 4,  Shulin Zhao # 1 2 3,  Qian Zhan # 1 2 3,  Peng Cui # 5,  Lingjie Ren 1 2 3,  Xuelong Wang 1 2 3,  Ruihong Zhang 4,  Chenxu Gao 4,  Yanting Zhou 4,  Shangli Cai 5,  Guoqiang Wang 5,  Wenchuan Xie 5,  Xiaomei Tang 1 2 3,  Minmin Shi 1 2 3,  Fangfang Ma 1 2 3,  Jia Liu 1 2 3,  Ting Wang 6,  Chaofu Wang 6,  Magali Svrcek 7,  Armelle Bardier-Dupas 8,  Jean Francois Emile 9,  Louis de Mestier 10,  Jean-Baptiste Bachet 11,  Remy Nicolle 12,  Jerome Cros 13,  Pierre Laurent-Puig 14,  Miaoyan Wei 15,  Bin Song 16,  Wei Jing 16,  Shiwei Guo 16,  Kailian Zheng 16,  Hui Jiang 16 17,  Huan Wang 16,  Xiaxing Deng 1 2 3,  Hao Chen 1 2 3,  Qiang Tian 4,  Shengyue Wang 4,  Si Shi 18,  Gang Jin 19,  Tong Yin 20,  Hai Fang 21,  Saijuan Chen 22,  Baiyong Shen 23 24 25
Affiliations

Affiliations

  • 1 Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 2 Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 3 State Key Laboratory of Systems Medicine for Cancer, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • 4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 5 Burning Rock Biotech, Guangzhou, China.
  • 6 Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 7 Department of Pathology, Saint-Antoine Hospital - Sorbonne Universités, Paris, France.
  • 8 Department of Pathology, Pitié-Salpêtrière Hospital - Sorbonne Universités, Paris, France.
  • 9 Department of Pathology, Ambroise Paré Hospital - Université Saint Quentin en Yvelines, Paris, France.
  • 10 Department of Pancreatology, Université Paris Cité - FHU MOSAIC, Beaujon Hospital, Clichy, France.
  • 11 Department of Gastroenterology, Pitié-Salpêtrière Hospital - Sorbonne Universités, Paris, France.
  • 12 Université Paris Cité, FHU MOSAIC, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, Paris, France.
  • 13 Department of Pathology, Université Paris Cité - FHU MOSAIC, Beaujon Hospital, Clichy, France.
  • 14 Department of Biochemistry, Hôpital Européen Georges Pompidou, Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS, Sorbonne Université, USPC, Université Paris Cité, Equipe labellisée Ligue Nationale contre le cancer, CNRS, Paris, France.
  • 15 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • 16 Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • 17 Department of Pathology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • 18 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. shisi@fudanpci.org.
  • 19 Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China. jingang@smmu.edu.cn.
  • 20 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. yintong0101@163.com.
  • 21 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. fh12355@rjh.com.cn.
  • 22 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. sjchen@stn.sh.cn.
  • 23 Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. shenby@shsmu.edu.cn.
  • 24 Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, China. shenby@shsmu.edu.cn.
  • 25 State Key Laboratory of Systems Medicine for Cancer, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China. shenby@shsmu.edu.cn.
  • # Contributed equally.
PMID: 38287168 DOI: 10.1038/s41591-023-02790-x
Abstract

Adjuvant chemotherapy benefits patients with resected pancreatic ductal adenocarcinoma (PDAC), but the compromised physical state of post-operative patients can hinder compliance. Biomarkers that identify candidates for prompt Adjuvant therapy are needed. In this prospective observational study, 1,171 patients with PDAC who underwent pancreatectomy were enrolled and extensively followed-up. Proteomic profiling of 191 patient samples unveiled clinically relevant functional protein modules. A proteomics-level prognostic risk model was established for PDAC, with its utility further validated using a publicly available external cohort. More importantly, through an interaction effect regression analysis leveraging both clinical and proteomic datasets, we discovered two biomarkers (NDUFB8 and CEMIP2), indicative of the overall sensitivity of patients with PDAC to Adjuvant chemotherapy. The biomarkers were validated through immunohistochemistry on an internal cohort of 386 patients. Rigorous validation extended to two external multicentic cohorts-a French multicentric cohort (230 patients) and a cohort from two grade-A tertiary hospitals in China (466 patients)-enhancing the robustness and generalizability of our findings. Moreover, experimental validation through functional assays was conducted on PDAC cell lines and patient-derived organoids. In summary, our cohort-scale integration of clinical and proteomic data demonstrates the potential of proteomics-guided prognosis and biomarker-aided Adjuvant chemotherapy for PDAC.

Figures
Products